Association between the use of protease inhibitors in Highly Active Antiretroviral Therapy (HAART) and incidence of metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis

2.50
Hdl Handle:
http://hdl.handle.net/10757/622686
Title:
Association between the use of protease inhibitors in Highly Active Antiretroviral Therapy (HAART) and incidence of metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis
Authors:
Echecopar-Sabogal, Jose ( 0000-0002-5754-6421 ) ; D'Angelo-Piaggio, Lorenzo ( 0000-0003-4092-6601 )
Advisors:
Ugarte Gil, Cesar
Citation:
1. Echecopar-Sabogal J, D’Angelo-Piaggio L, Chanamé-Baca DM, Ugarte-Gil C. Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis [Internet]. International Journal of STD & AIDS. Universidad Peruana de Ciencias Aplicadas (UPC); 2017. Available from: http://hdl.handle.net/10757/622686
Publisher:
Universidad Peruana de Ciencias Aplicadas (UPC)
Issue Date:
1-Jan-2017
URI:
http://hdl.handle.net/10757/622686
Abstract:
Introduction: Since its introduction, Highly Active Antiretroviral Treatment (HAART) has been shown to prolong the life expectancy of HIV-infected patients. HIV and HAART, especially protease inhibitors (PIs), have been associated with the occurrence of Metabolic Syndrome (MS). The objective of this systematic review and meta-analysis was to determine whether there is an association between the use of PIs and the incidence of MS in HIV-infected patients. Methods: A comprehensive search (including databases such as MEDLINE/PubMed, CENTRAL, LILACS and EMBASE) was performed. Observational studies published until November 2015 were included. Inclusion criteria for primary studies were: study population comprised HIV-infected patients aged 18 years or older and who were receiving HAART; patients assessed according to their use of PIs; DM as defined by the primary study. Heterogeneity was assessed and a pooled analysis was performed using a random-effects model. Results: 3 articles met the inclusion criteria, describing 586 HIV patients. Use of PIs was associated with the development of MS (RR: 2.11; 95% CI 1.28 to 3.48; 〖Chi〗^2:0.04, I^2: 0%; p-value 0.003). Conclusion: Use of PIs in HIV-infected patients is associated with an increased risk of MS. These findings are of relevance for future public policy because it will increase the interest in screening and prevention of MS in an expanding population.
Type:
info:eu-repo/semantics/bachelorThesis
Rights:
info:eu-repo/semantics/embargoedAccess
Language:
spa

Full metadata record

DC FieldValue Language
dc.contributor.advisorUgarte Gil, Cesares
dc.contributor.authorEchecopar-Sabogal, Josees
dc.contributor.authorD'Angelo-Piaggio, Lorenzoes
dc.date.accessioned2018-02-15T01:57:47Z-
dc.date.available2018-02-15T01:57:47Z-
dc.date.issued2017-01-01-
dc.identifier.citation1. Echecopar-Sabogal J, D’Angelo-Piaggio L, Chanamé-Baca DM, Ugarte-Gil C. Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis [Internet]. International Journal of STD & AIDS. Universidad Peruana de Ciencias Aplicadas (UPC); 2017. Available from: http://hdl.handle.net/10757/622686es_PE
dc.identifier.urihttp://hdl.handle.net/10757/622686-
dc.description.abstractIntroduction: Since its introduction, Highly Active Antiretroviral Treatment (HAART) has been shown to prolong the life expectancy of HIV-infected patients. HIV and HAART, especially protease inhibitors (PIs), have been associated with the occurrence of Metabolic Syndrome (MS). The objective of this systematic review and meta-analysis was to determine whether there is an association between the use of PIs and the incidence of MS in HIV-infected patients. Methods: A comprehensive search (including databases such as MEDLINE/PubMed, CENTRAL, LILACS and EMBASE) was performed. Observational studies published until November 2015 were included. Inclusion criteria for primary studies were: study population comprised HIV-infected patients aged 18 years or older and who were receiving HAART; patients assessed according to their use of PIs; DM as defined by the primary study. Heterogeneity was assessed and a pooled analysis was performed using a random-effects model. Results: 3 articles met the inclusion criteria, describing 586 HIV patients. Use of PIs was associated with the development of MS (RR: 2.11; 95% CI 1.28 to 3.48; 〖Chi〗^2:0.04, I^2: 0%; p-value 0.003). Conclusion: Use of PIs in HIV-infected patients is associated with an increased risk of MS. These findings are of relevance for future public policy because it will increase the interest in screening and prevention of MS in an expanding population.es
dc.description.uriTesises_PE
dc.formatapplication/pdfes
dc.formatapplication/epubes
dc.formatapplication/mswordes
dc.language.isospaes
dc.publisherUniversidad Peruana de Ciencias Aplicadas (UPC)es
dc.rightsinfo:eu-repo/semantics/embargoedAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)es_PE
dc.sourceRepositorio Académico - UPCes_PE
dc.titleAssociation between the use of protease inhibitors in Highly Active Antiretroviral Therapy (HAART) and incidence of metabolic syndrome in HIV-infected patients: A systematic review and meta-analysises
dc.typeinfo:eu-repo/semantics/bachelorThesises
thesis.degree.grantorUniversidad Peruana de Ciencias Aplicadas (UPC). Facultad de Ciencias de la Saludes_PE
thesis.degree.levelLicenciaturaes_PE
thesis.degree.disciplineMedicinaes_PE
thesis.degree.nameMédico cirujanoes_PE
This item is licensed under a Creative Commons License
Creative Commons
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.